Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities... Read more.
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities... Read more.
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with... Read more.
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with... Read more.
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with... Read more.
PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026
Two-year and post-hoc SURPASS-ET analyses highlight the impact of treatment timing, with durable responses and improved progression-free survival supporting consideration... Read more.
ISG to Study UKG Pro Ecosystem Service Providers
Upcoming ISG Provider Lens® report will evaluate providers that modernize workforce operations with AI, data integration and continuous optimization STAMFORD, Conn.–(BUSINESS... Read more.
ISG to Study UKG Pro Ecosystem Service Providers
Upcoming ISG Provider Lens® report will evaluate providers that modernize workforce operations with AI, data integration and continuous optimization STAMFORD, Conn.–(BUSINESS... Read more.
ISG to Study UKG Pro Ecosystem Service Providers
Upcoming ISG Provider Lens® report will evaluate providers that modernize workforce operations with AI, data integration and continuous optimization STAMFORD, Conn.–(BUSINESS... Read more.
ZFLOW AI’s Simulation-Guided Optimization Identifies a 1.54× Higher-Throughput Serving Configuration for DeepSeek V4-Pro on 8×B300
Working on PaleBlueDot AI’s NVIDIA B300 platform, ZFLOW AI used hardware-aware simulation to find an optimized SGLang serving configuration for high-concurrency... Read more.